Etalanetug vs VY7523

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Alzheimer's Disease

Shared mechanism: Tau (monoclonal antibody) · full Alzheimer's Disease pipeline

Etalanetug

Developed by Eisai

Phase 2/3 in Alzheimer's Diseasemonoclonal antibody
Weak signal

NCT04971733 · Phase 1/2 · completed

The study treated 8 participants with etalanetug (E2814, Eisai's development code for this antibody) in open-label, single-arm cohorts without randomization, blinding or a comparator. Its primary endpoint was safety (treatment-emergent adverse events), not a controlled efficacy comparison, so it is weak evidence of efficacy.

Next expected readout: December 2026 · NCT06602258 (registry estimate)

Reported efficacy

Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious TEAEs (From first dose of study drug up to 120 weeks); Number of Participants With Markedly Abnormal Laboratory Values (From first dose of study drug up to 120 weeks); Number of Participants With Clinically Significant Change in Vital Signs Values (From first dose of study drug up to 120 weeks); Number of Participants With Clinically Significant Change in Electrocardiogram (ECG) Findings (From first dose of study drug up to 120 weeks); Cohort A: Change From Baseline in Cerebrospinal Fluid (CSF) Free, CSF Bound and Total Microtubule Binding Region of Tau (MTBR-tau; Starting at Amino Acid 354 and 299) at 12 Weeks (Pre-dose at Week 12): Safety: three participants had treatment-related adverse events at the 3000 mg dose, and 5 serious adverse events occurred in 3 participants. Target engagement: CSF MTBR-tau243 fell 50.6% after 12 weeks (n=7), with a maximum reduction of 71.6% at week 36 (n=4); CSF ptau217 fell 30.4% at 12 weeks (n=7). Eight participants enrolled; no control group. (not_applicable)

Result source: NCT04971733

VY7523

Developed by Voyager Therapeutics

Phase 1/2 in Alzheimer's Diseasemonoclonal antibody
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

Results for Alzheimer's Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointEtalanetugVY7523
CDR-SB, change—Trial running · NCT01760005—Not reported
ADAS-Cog11, change—Trial running · NCT01760005—Not reported
ADCS-ADL, change—Trial running · NCT01760005—Not reported
MMSE, change—Trial running · NCT01760005—Not reported
Amyloid PET, change (centiloids)—Trial running · NCT01760005—Not reported

CDR-SB, change

Etalanetug
—Trial running · NCT01760005
VY7523
—Not reported

ADAS-Cog11, change

Etalanetug
—Trial running · NCT01760005
VY7523
—Not reported

ADCS-ADL, change

Etalanetug
—Trial running · NCT01760005
VY7523
—Not reported

MMSE, change

Etalanetug
—Trial running · NCT01760005
VY7523
—Not reported

Amyloid PET, change (centiloids)

Etalanetug
—Trial running · NCT01760005
VY7523
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

VY7523: no structured comparison results are available for Alzheimer's Disease.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Etalanetug: 2 of 4 rows · VY7523: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricEtalanetug
Dropout rate
—4500 mga
NCT04971733 · Phase 1/2
show 2 more results
—1500 mg
NCT04971733 · Phase 1/2
—750 mg
NCT04971733 · Phase 1/2
Discontinued due to AEs
—4500 mga
NCT04971733 · Phase 1/2
show 2 more results
—1500 mg
NCT04971733 · Phase 1/2
—750 mg
NCT04971733 · Phase 1/2
Serious AEs
25%4500 mga
NCT04971733 · Phase 1/2
show 2 more results
0%1500 mg
NCT04971733 · Phase 1/2
0%750 mg
NCT04971733 · Phase 1/2
Most frequent reported AEs
4500 mga
upper respiratory tract infection 50%
agitation 25%
aphasia 25%
NCT04971733 · Phase 1/2
show 2 more results
1500 mg
bundle branch block left 14.3%
genital herpes 14.3%
agitation 0%
NCT04971733 · Phase 1/2
750 mg
covid-19 28.6%
chronic pigmented purpura 14.3%
diarrhoea 14.3%
NCT04971733 · Phase 1/2

Notes

  1. aPopulation comparability has not been reviewed for these studies.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Etalanetug's landscape · VY7523's landscape